41276-02-2 Usage
Uses
Used in Pharmaceutical Industry:
7-Benzyl-10-(2-Methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3H)-one is used as an anticancer agent for the treatment of various types of cancer. 7-benzyl-10-(2-Methylbenzyl)-2,6,7,8,9,10-hexahydroiMidazo[1,2-a]pyrido[4,3-d]pyriMidin-5(3H)-one works by inducing the TRAIL gene in both normal and tumor cells, which can lead to the activation of apoptosis and the subsequent death of cancer cells. This makes it a promising candidate for the development of new cancer therapies.
Additionally, the compound has been the subject of a resolution in Chemical and Engineering News, highlighting its correct characterization as B285480, which was previously assigned the structure of NSC 350625. This clarification is important for the accurate identification and use of the compound in future research and development efforts within the pharmaceutical industry.
Biological Activity
tic10 (trail-inducing compound 10) is a potent and stable small molecule that is orally active. it induces trail transcriptionally independent of p53 and crosses the blood-brain barrier. [1]tumor necrosis factor-related apoptosis-inducing ligand (trail) is an apoptosis inducer in a variety of human cancer cell lines. it also acts as a tumor suppressor during immune surveillance but the function is lost in cancer progression. [1]tic10 caused a prominent and long-lasting production of trail on cell surface of tumor cell.tic10 also led to trail-mediated apoptosis in hct116 p53-/- cells. in addition, tic10 inactivated akt and erk cooperatively lead to the nuclear translocation of foxo3a and ensuing trail up-regulation. [1]in mouse caner xenograft, tic10 showed trail-dependent antitumor effect. it caused tumor-specific cell death by rail-mediated direct and bystander effects. tic10 is also an effective antitumor agent for orthotopic human glioblastoma multiforme tumors. [1]
references
1. allen je, krigsfeld g, mayes pa et al. dual inactivation of akt and erk by tic10 signals foxo3a nuclear translocation, trail gene induction, and potent antitumor effects. sci transl med. 2013 feb 6;5(171):171ra17.
Check Digit Verification of cas no
The CAS Registry Mumber 41276-02-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,1,2,7 and 6 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 41276-02:
(7*4)+(6*1)+(5*2)+(4*7)+(3*6)+(2*0)+(1*2)=92
92 % 10 = 2
So 41276-02-2 is a valid CAS Registry Number.
InChI:InChI=1/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-22-11-13-26(15-19-8-3-2-4-9-19)17-21(22)23(29)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3
41276-02-2Relevant academic research and scientific papers
PHARMACOPHORE FOR TRAIL INDUCTION
-
, (2017/05/07)
There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidin
Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL
Jacob, Nicholas T.,Lockner, Jonathan W.,Kravchenko, Vladimir V.,Janda, Kim D.
, p. 6628 - 6631 (2014/07/08)
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is an immunosurveillance cytokine that kills cancer cells but demonstrates little toxicity against normal cells. While investigating the TRAIL-inducing imidazolinopyrimidinone TIC10, a misassignment of its active structure was uncovered. Syntheses of the two isomers, corresponding to the published and reassigned structures, are reported. The ability of each to induce TRAIL expression in macrophages was investigated and it was found that only the compound corresponding to the reassigned structure shows the originally reported activity; the compound corresponding to the published structure is inactive. Importantly, this structural reassignment has furnished a previously unknown antitumor pharmacophore. Setting the record straight: An investigation of an imidazolinopyrimidinone (TIC10) reported to induce expression of the immunosurveillance cytokine TRAIL led to a constitutional reassignment of the active pharmacophore. Analysis of TRAIL induction in macrophages revealed the reported structure to be inactive. The structural identity of the active compound was established. The active compound was then synthesized and its activity confirmed.
